Connection

Anjan Trikha to Immunologic Factors

Back to Details
This is a "connection" page, showing publications Anjan Trikha has written about Immunologic Factors.
Anjan Trikha
Connection Strength
0.069
Immunologic Factors
  1. A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19. Expert Opin Biol Ther. 2021 05; 21(5):675-686.
    View in: PubMed
    Score: 0.069
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.